Rapidly Evolving Landscape and Future Horizons in Hepatocellular Carcinoma in the Era of Immuno-Oncology.

Front Oncol · 2022 · PMC9008732 · PMID 35433430

Europe PMC DOI

hedged sentence

0.0752

closest p · 1.5× alpha

0.0752

boldest claim

The sentences

showed a trendp=0.0752so close (0.05 < p ≤ 0.1)

Although the primary endpoint of OS did not meet the predefined threshold of statistical significance (HR 0.83, p=0.0419), nivolumab showed a trend towards improved median OS (16.4 vs. 14.7 months; HR 0.85, p=0.0752) and ORR (15% vs. 7%) compared to sorafenib.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.